Oral butyrate for mildly to moderately active Crohn's disease
Oral butyrate for mildly to moderately active Crohn's disease
复制标题
DOI：
10.1111/j.1365-2036.2005.02639.x
复制
发表时间：
2005-11-01
影响因子：
7.6
通讯作者：
Corazza, GR
中科院分区：
文献类型：
--
作者：
Di Sabatino, A;Morera, R;Corazza, GR
背景资料：丁酸盐在实验性结肠炎和克罗恩病固有层单核细胞中发挥抗炎作用。目的：探讨口服丁酸盐治疗克罗恩病的有效性和安全性。方法：13例轻中度回结肠克罗恩病患者接受4 g/天丁酸盐肠溶片治疗8周。治疗前后均行全结肠镜和回肠镜检查。内镜和组织学评分，实验室数据，克罗恩病活动指数和粘膜白细胞介素（IL）-1 β，IL-6，IL-12，干扰素-γ，肿瘤坏死因子-α和核因子-κ B（NF-κ B）进行了评估治疗前后。在对治疗有反应的9名患者（69%）中，7名（53%）达到缓解，2名部分缓解。回盲部内镜评分和组织学评分治疗后明显改善（P < 0.05）。结论：口服丁酸钠治疗克罗恩病安全，耐受性好，可有效改善或缓解克罗恩病的临床症状。这些数据表明，需要进行大规模的研究，以扩大目前的研究结果，并表明丁酸可能发挥其作用，通过下调NF-κ B和IL-1 β。
Background: Butyrate exerts anti-inflammatory effects in experimental colitis and on Crohn's disease lamina propria mononuclear cells in vitro.Aim: To explore the efficacy and safety of oral butyrate in Crohn's disease.Methods: Thirteen patients with mild-moderate ileocolonic Crohn's disease received 4 g/day butyrate as enteric-coated tablets for 8 weeks. Full colonoscopy and ileoscopy were performed before and after treatment. Endoscopical and histological score, laboratory data, Crohn's disease activity index and mucosal interleukin (IL)-1 beta, IL-6, IL-12, interferon-gamma, tumour necrosis factor-alpha and nuclear factor-kappa B (NF-kappa B) were assessed before and after treatment.Results: One patient withdrew from the study, and three patients did not experience clinical improvement. Among the nine patients (69%) who responded to treatment, seven (53%) achieved remission and two had a partial response. Endoscopical and histological score significantly improved after treatment at ileocaecal level (P < 0.05). Leucocyte blood count, erythrocyte sedimentation rate and mucosal levels of NF-kappa B and IL-1 beta significantly decreased after treatment (P < 0.05).Conclusions: Oral butyrate is safe and well tolerated, and may be effective in inducing clinical improvement/remission in Crohn's disease. These data indicate the need for a large investigation to extend the present findings, and suggest that butyrate may exert its action through downregulation of NF-kappa B and IL-1 beta.